What's done is done. At this point I don't see why they should worry about the stock not trading before there is progress on developing the tests. They've said they aren't using the stock to raise money (how could they) so there's really no benefit to the company or stock (I doubt .02) without some major event occurring.

There was no timelines or order of events given, after the test is being produced and mostly ready for FDA review it may make sense to worry about the stock.

Perhaps next New Years Newsletter will be more interesting.